Supergenerics May Offer Low Risk Strategy in Developing New Medicines, According to GBI Research

17 May 2012 • by Natalie Aster

The development of supergenerics which are also known as "hybrids", "new therapeutic entities" or "value-added generics" aims to address specific patient or clinical needs. For example, supergeneric companies have developed new drug formulations which are appropriate for use in pediatric or geriatrics, or developed different doses, combination or modified release formulations to improve patient compliance. Alternatively they have targeted specific therapeutic needs, such as in oncology, where drugs may be associated with a narrow therapeutic window and new formulations may help to reduce peripheral toxicities.

According to the report “Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets” by GBI Research, the development of supergenerics may offer a low risk, low-cost strategy in the development of new medicines compared to traditional pharmaceutical product development. This is due to a number of reasons including a shorter development timeline, a simpler clinical development process and longer market exclusivity.

Report Details:

Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets
Published: April, 2012
Pages: 70
Price: US$ 3.500,00

GBI Research analysis has identified more than 60 novel supergeneric formulations of approved oncology, CNS and pain, and respiratory products that are under development to address specific unmet medical needs.

Many of these products are in development by specialty pharma or drug delivery specialists which have limited commercialization expertise and are seeking developmental partners. This highlights the significant commercial opportunities available to companies wishing to develop supergenerics (internal and external strategies) to enhance their portfolios and leverage their expertise to develop drugs which target both the developed and emerging markets.

More information can be found in the report “Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets” by GBI Research.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com